GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenwich LifeSciences Inc (NAS:GLSI) » Definitions » Asset Turnover

Greenwich LifeSciences (Greenwich LifeSciences) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Greenwich LifeSciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Greenwich LifeSciences's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Greenwich LifeSciences's Total Assets for the quarter that ended in Mar. 2024 was $6.25 Mil. Therefore, Greenwich LifeSciences's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Greenwich LifeSciences's annualized ROE % for the quarter that ended in Mar. 2024 was -167.36%. It is also linked to ROA % through Du Pont Formula. Greenwich LifeSciences's annualized ROA % for the quarter that ended in Mar. 2024 was -158.21%.


Greenwich LifeSciences Asset Turnover Historical Data

The historical data trend for Greenwich LifeSciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenwich LifeSciences Asset Turnover Chart

Greenwich LifeSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial - - - - -

Greenwich LifeSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Greenwich LifeSciences's Asset Turnover

For the Biotechnology subindustry, Greenwich LifeSciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenwich LifeSciences's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Greenwich LifeSciences's Asset Turnover falls into.



Greenwich LifeSciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Greenwich LifeSciences's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (13.477+6.995)/ 2 )
=0/10.236
=0.00

Greenwich LifeSciences's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (6.995+5.51)/ 2 )
=0/6.2525
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Greenwich LifeSciences  (NAS:GLSI) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Greenwich LifeSciences's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-9.892/5.9105
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-9.892 / 0)*(0 / 6.2525)*(6.2525/ 5.9105)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.0579
=ROA %*Equity Multiplier
=-158.21 %*1.0579
=-167.36 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Greenwich LifeSciences's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-9.892/6.2525
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-9.892 / 0)*(0 / 6.2525)
=Net Margin %*Asset Turnover
= %*0
=-158.21 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Greenwich LifeSciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of Greenwich LifeSciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenwich LifeSciences (Greenwich LifeSciences) Business Description

Traded in Other Exchanges
N/A
Address
3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.
Executives
Snehal Patel director, officer: CHIEF EXECUTIVE OFFICER 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Jaye Thompson officer: VPC AND REGULATORY AFFAIRS 2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Frank Joseph Daugherty director, officer: CHIEF MEDICAL OFFICER 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kenneth Hallock director 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
David Mcwilliams director 2575 WEST BELLFORT STREET, HOUSTON TX 77054-9816
Eric Rothe director 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kinnary Patel 10 percent owner 3992 BLUEBONNET DR., BUILDING 14, STAFFORD TX 77477
Panjaj Amrit Patel 10 percent owner 50726 LAKESIDE DRIVE, GRANGER IN 46530

Greenwich LifeSciences (Greenwich LifeSciences) Headlines

From GuruFocus

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

By Business Wire Business Wire 02-03-2022

Could Insider Buying Signal that Greenwich LifeSciences Inc Is Undervalued?

By GuruFocus Research GuruFocus Editor 01-31-2023

Could Insider Buying Signal that Greenwich LifeSciences Inc Is Undervalued?

By GuruFocus Research GuruFocus Editor 12-20-2022